Human Metabolome Technologies Past Earnings Performance
Past criteria checks 3/6
Human Metabolome Technologies has been growing earnings at an average annual rate of 70.9%, while the Life Sciences industry saw earnings growing at 28.2% annually. Revenues have been growing at an average rate of 8.4% per year. Human Metabolome Technologies's return on equity is 15.9%, and it has net margins of 21.3%.
Key information
70.9%
Earnings growth rate
71.0%
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | 8.4% |
| Return on equity | 15.9% |
| Net Margin | 21.3% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Human Metabolome Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,321 | 282 | 467 | 185 |
| 30 Sep 23 | 1,272 | 264 | 452 | 185 |
| 30 Jun 23 | 1,299 | 285 | 454 | 185 |
| 31 Mar 23 | 1,288 | 214 | 498 | 158 |
| 31 Dec 22 | 1,300 | 259 | 499 | 158 |
| 30 Sep 22 | 1,312 | 298 | 490 | 158 |
| 30 Jun 22 | 1,223 | 267 | 486 | 158 |
| 31 Mar 22 | 1,208 | 246 | 533 | 98 |
| 31 Dec 21 | 1,120 | 147 | 579 | 98 |
| 30 Sep 21 | 1,052 | 46 | 617 | 98 |
| 30 Jun 21 | 1,124 | 58 | 663 | 98 |
| 31 Mar 21 | 1,051 | -42 | 655 | 155 |
| 31 Dec 20 | 1,201 | 64 | 652 | 155 |
| 30 Sep 20 | 1,165 | 5 | 695 | 155 |
| 30 Jun 20 | 1,118 | -47 | 718 | 155 |
| 30 Jun 19 | 839 | -469 | 778 | 189 |
| 31 Mar 19 | 834 | -359 | 943 | 0 |
| 31 Dec 18 | 857 | -312 | 697 | 235 |
| 30 Sep 18 | 907 | -217 | 660 | 235 |
| 30 Jun 18 | 971 | -151 | 672 | 235 |
| 31 Mar 18 | 938 | -156 | 648 | 235 |
| 31 Dec 17 | 923 | -182 | 689 | 209 |
| 30 Sep 17 | 948 | -130 | 675 | 209 |
| 30 Jun 17 | 938 | -70 | 604 | 209 |
| 31 Mar 17 | 914 | -61 | 563 | 209 |
| 31 Dec 16 | 840 | -74 | 577 | 139 |
| 30 Sep 16 | 754 | -119 | 524 | 139 |
| 30 Jun 16 | 784 | -82 | 509 | 139 |
| 31 Mar 16 | 780 | -71 | 502 | 139 |
| 31 Dec 15 | 783 | 16 | 489 | 122 |
| 30 Sep 15 | 743 | -9 | 480 | 122 |
| 30 Jun 15 | 684 | -57 | 469 | 122 |
| 31 Mar 15 | 686 | -34 | 444 | 122 |
| 31 Dec 14 | 630 | -108 | 441 | 89 |
| 30 Sep 14 | 649 | -74 | 413 | 89 |
| 30 Jun 14 | 600 | -58 | 370 | 89 |
| 31 Mar 14 | 610 | 1 | 335 | 89 |
Quality Earnings: 6090 has a high level of non-cash earnings.
Growing Profit Margin: 6090's current net profit margins (21.3%) are higher than last year (19.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6090 has become profitable over the past 5 years, growing earnings by 70.9% per year.
Accelerating Growth: 6090's earnings growth over the past year (8.9%) is below its 5-year average (70.9% per year).
Earnings vs Industry: 6090 earnings growth over the past year (8.9%) exceeded the Life Sciences industry -19.3%.
Return on Equity
High ROE: 6090's Return on Equity (15.9%) is considered low.